Bothell-based BioLife Solutions, Inc. announced that Amsterdam-based Kiadis Pharma has incorporated the company’s clinical grade HypoThermosol cell and tissue storage and shipping medium into its collection process for donor leukocytes that forms the basis of Kiadis’ ATIR101TM T cell product targeting patients with various blood cancers.

Biolife is developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, while Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative T cell immunotherapy treatments for blood cancers and inherited blood disorders.

“We are very pleased to support Kiadis in their development of potentially life saving cellular immunotherapies for cancer patients,” said BioLife’s President and CEO Mike Rice. “It’s very satisfying to see the clinical community focus on shelf life and viability as key criteria for potential commercialization of novel cell therapies. HypoThermosol and our companion CryoStor freeze media are now embedded in over 200 pre-clinical validations and clinical trials of numerous cell-based products and therapies, with a significant concentration in applications of various T cell therapies.”

In addition to Kiadis, a large majority of the currently active private and public cellular immunotherapy companies have adopted BioLife’s biopreservation media products including HypoThermosol and CryoStor to extend stability and improve viability and functional recovery of starting material and manufactured cell products.